Singletto develops antimicrobial solutions that utilize singlet oxygen technology to effectively eliminate pathogens from surfaces and air. This technology enhances safety in various environments by providing measurable protection against harmful microorganisms.
Funding
$390K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of pathogen protection often rely on trapping or shielding pathogens, or provide only one-time disinfection, failing to actively destroy pathogens during prolonged use. This leaves a gap in providing continuous protection against harmful microorganisms in various environments.
Solution
Singletto is developing Oxafence, an Antimicrobial Photodynamic Inactivation (aPDI) technology that provides ongoing active protection from pathogens. Oxafence utilizes protective dyes that absorb and transfer energy to oxygen in the air, creating singlet oxygen, which inactivates viruses and bacteria. This technology applies principles of Photodynamic Therapy (PDT) to inactivate pathogens on surfaces and within materials. Singletto's technology is designed for integration into commonly used materials and fabrics, offering continuous inactivation of pathogens like SARS-CoV-2 and H1N1.
Target Audience
The primary target audience includes healthcare providers, military personnel, industrial workers, and consumers seeking continuous antimicrobial protection.
Features
- Oxafence technology utilizes Antimicrobial Photodynamic Inactivation (aPDI) to inactivate pathogens.
- Protective dyes absorb and transfer energy to oxygen, creating singlet oxygen with antimicrobial properties.
- Demonstrated ongoing inactivation of SARS-CoV-2, H1N1, and other viruses and bacteria in treated materials.
- Currently FDA-cleared in ProGear Surgical Masks with Oxafence.
- Technology is being developed for application to various materials and fabrics.